You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Moodys
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: April 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Idalopirdine


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Idalopirdine?

Idalopirdine is an investigational drug.

There have been 7 clinical trials for Idalopirdine. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Alzheimer Disease and [disabled in preview]. The leading clinical trial sponsors are H. Lundbeck A/S and [disabled in preview].

There are thirteen US patents protecting this investigational drug and one hundred and seventy-six international patents.

Recent Clinical Trials for Idalopirdine
TitleSponsorPhase
Positron Emission Tomography (PET) Study in Patients With Alzheimer's DiseaseH. Lundbeck A/SPhase 1
Bioequivalence Study of Idalopirdine in Healthy SubjectsH. Lundbeck A/SPhase 1
Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy MenH. Lundbeck A/SPhase 1

See all Idalopirdine clinical trials

Clinical Trial Summary for Idalopirdine

Top disease conditions for Idalopirdine
Top clinical trial sponsors for Idalopirdine

See all Idalopirdine clinical trials

US Patents for Idalopirdine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Idalopirdine   Start Trial Polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzyla- mine hydrochloride for the treatment of Alzheimer's disease H. LUNDBECK A/S (Valby, DK)   Start Trial
Idalopirdine   Start Trial Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients H. LUNDBECK A/S (Valby, DK)   Start Trial
Idalopirdine   Start Trial N-(2-Arylethyl) benzylamines as antagonists of the 5-HT.sub.6 receptor Eli Lilly and Company (Indianapolis, IN)   Start Trial
Idalopirdine   Start Trial N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor Eli Lilly (Indianapolis, IN)   Start Trial
Idalopirdine   Start Trial Tryptamine sulfonamides as 5-HT.sub.6 antagonists Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Idalopirdine

Drugname Country Document Number Estimated Expiration Related US Patent
Idalopirdine Argentina 101109 2034-07-04   Start Trial
Idalopirdine Australia 2015282909 2034-07-04   Start Trial
Idalopirdine Brazil 112017000127 2034-07-04   Start Trial
Idalopirdine Canada 2951794 2034-07-04   Start Trial
Idalopirdine Chile 2017000002 2034-07-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Moodys
Medtronic
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.